Onconetix, Inc. (ONCO)
NCM – Real Time Price. Currency in USD
0.41
+0.01 (1.42%)
At close: May 12, 2026, 4:00 PM EDT
0.41
-0.00 (-0.20%)
Pre-market: May 13, 2026, 5:33 AM EDT
Find any stock by ticker or company name

NCM – Real Time Price. Currency in USD
0.41
+0.01 (1.42%)
At close: May 12, 2026, 4:00 PM EDT
0.41
-0.00 (-0.20%)
Pre-market: May 13, 2026, 5:33 AM EDT
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.
| Name | Position |
|---|---|
| Dr. Ali I. Fattom Ph.D. | Head of Science & Discovery |
| Dr. Brian Price Ph.D. | Head of Technology Strategy |
| Dr. Jay Newmark M.B.A., M.D. | Chief Medical Officer |
| Mr. Andrew D. Skibo Ph.D. | Global Head of Biologics Operations |
| Mr. David Allan White C.A., C.P.A., ICD.D | Chief Executive Officer |
| Mr. Theodore Scott Yoho | Head of Business Development |
| Ms. Karina M. Fedasz | Interim Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | S-1/A | ea0289698-s1a1_onconetix.htm |
| 2026-05-07 | POS AM | ea0289278-posam1_onconetix.htm |
| 2026-05-04 | 8-K | ea0288982-8k_onconetix.htm |
| 2026-04-28 | S-1 | ea0287904-s1_onconetix.htm |
| 2026-04-24 | 8-K | ea0287604-8k_onconetix.htm |
| 2026-04-09 | 425 | eea0285711-425_onconetix.htm |
| 2026-04-02 | 425 | ea0284775-425_onconetix.htm |
| 2026-03-31 | 425 | ea0284179-425_onconetix.htm |
| 2026-03-30 | DEF 14A | ea0283690-def14a_onconetix.htm |
| 2026-03-27 | 8-K | ea0283569-8k_onconetix.htm |